ABSTRACT
Hydrocortisone replacement therapy is a cornerstone in the treatment of adrenal insufficiency (AI). While urinary cortisol has been used as a diagnostic tool for AI, it remains unclear whether it is a useful parameter to monitor hydrocortisone replacement therapy. Aim of this study was to evaluate possible differences in cortisol metabolism between adrenal insufficient patients and healthy subjects and to assess the value of urinary cortisol in AI management. In a case-control study, urinary cortisol excretion was determined in 14 patients with primary and secondary AI receiving hydrocortisone infusions from midnight to 8:00 AM. Results were correlated with serum cortisol levels and compared to urinary values obtained from 53 healthy volunteers. Urinary cortisol excretion in healthy subjects was 14.0±7.8 µg/8 h (range: 0.24-35.4), levels did not differ between 3 groups aged 20-34 years, 35-49 years, and ≥50 years. Patients with AI receiving hydrocortisone infusions demonstrated significantly higher rates of urinary cortisol excretion (51.6±37.8 µg/8 h; range 17.1-120.0, p<0.001); the values correlated with serum cortisol levels (r(2)=0.98). Of interest, patients with secondary AI showed significantly higher serum cortisol levels after hydrocortisone infusion than those with primary AI, conceivably due to residual adrenal function. In conclusion, we showed that: (i) there is a wide inter-individual variability in urinary cortisol excretion rates; (ii) cortisol metabolism in adrenal insufficient patients differs when compared to controls; (iii) there is a strong correlation between urinary and serum cortisol levels; and (iv) urinary cortisol levels despite their variability may help to discriminate between secondary and primary adrenal insufficiency.
Subject(s)
Adrenal Insufficiency/drug therapy , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/urine , Hormone Replacement Therapy , Hydrocortisone/administration & dosage , Hydrocortisone/urine , Adrenal Insufficiency/urine , Adult , Aged , Case-Control Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , PrognosisABSTRACT
OBJECTIVES: To validate the diagnostic utility of Cortrosyn(™) stimulated aldosterone in the differentiation of primary (PAI) and secondary adrenal insufficiency (SAI) and to evaluate the effect of urine sodium levels and posture on test performance. DESIGN: Cross-sectional study. METHODS: Healthy volunteers (HV; n = 46) and patients with PAI (n = 26) and SAI (n = 29) participated in the study. Testing included cortisol and aldosterone (by liquid-chromatography tandem mass spectrometry) measurements at baseline and 30 and 60 min after 250 µg Cortrosyn(™). Plasma corticotropin (ACTH), renin activity (PRA) and urine spot sodium as a proxy for 24-h urine sodium excretion were measured at baseline. The effect of a sitting or semifowlers posture was evaluated in healthy volunteers. RESULTS: A Cortrosyn(™)-stimulated aldosterone level of 5 ng/dl (0·14 nmol/l) had 88% sensitivity and positive predictive value and 89·7% specificity and negative predictive value for distinguishing PAI from SAI. Spot urine sodium levels showed a strong correlation with peak aldosterone levels (r = -0·55, P = 0·02, n = 18) in the SAI but not PAI or HV groups. Posture did not have a significant effect on results. CONCLUSIONS: Once diagnosed with adrenal insufficiency, a stimulated aldosterone value of 5 ng/dl (0·14 nmol/l) works well to differentiate PAI from SAI. However, clinicians should be aware of the possible effect of total body sodium as reflected by spot urine sodium levels on aldosterone results. A 24-h urine sodium measurement may be helpful in interpretation.
Subject(s)
Adrenal Insufficiency/blood , Adrenocorticotropic Hormone/blood , Pituitary-Adrenal Function Tests/methods , Tandem Mass Spectrometry/methods , Adrenal Insufficiency/diagnosis , Adrenal Insufficiency/urine , Adrenocorticotropic Hormone/administration & dosage , Adult , Aldosterone/blood , Cosyntropin/administration & dosage , Cosyntropin/blood , Cross-Sectional Studies , Female , Humans , Hydrocortisone/blood , Male , Middle Aged , Reference Values , Renin/blood , Reproducibility of Results , Sensitivity and Specificity , Sodium/urineABSTRACT
PURPOSE: Cortisol plays an important role in the physical status of patients with end-stage lung cancer, but the association of urine cortisol levels with TNM stage/performance status (PS) is unclear in patients with advanced lung cancer receiving chemotherapy. The objective of this study was to examine this association. METHODS: In this single-center, retrospective, observational study, cortisol concentrations in 24-h pooled urine from 22 patients with advanced lung cancer were measured over 2 days. The mean concentration in each patient was compared with PS, TNM stage, and serum sodium and potassium ion levels. RESULTS: The 24-h urine cortisol levels were higher in PS2 or PS3 cases compared to PS1 (p < 0.05) and increased proportionally with PS. Urine cortisol also increased in N2 or N3 cases compared to N1 (p < 0.01) and also increased in M1 cases (p < 0.05). Urine cortisol levels were negatively correlated with serum sodium (R = -0.49, p < 0.05) and had a tendency for a positive correlation with serum potassium (R = 0.40, p = 0.06). CONCLUSION: The 24-h urine cortisol level increased in patients with advanced lung cancer undergoing chemotherapy. Low serum levels of potassium and high levels of sodium may indicate relative adrenal insufficiency.
Subject(s)
Hydrocortisone/urine , Lung Neoplasms/urine , Adrenal Insufficiency/urine , Adult , Aged , Female , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
BACKGROUND: Asthma is routinely treated with inhaled corticosteroids (ICS). Asthma patients on ICS are at increased risk of adrenal suppression, a potentially serious effect of long-term glucocorticoid exposure; however, this relationship is poorly understood. Therefore, this study aims to identify metabolite biomarkers related to adrenal suppression in asthma patients taking ICS. METHODS: A total of 571 urine metabolites from 200 children with asthma on ICS in the Pharmacogenetics of Adrenal Suppression with Inhaled Steroids (PASS) cohort were profiled. Samples were grouped by peak plasma cortisol measurement as adrenal sufficient (>350 nmol/L) or insufficient (≤350 nmol/L) (outcome). Regression and discriminant-based statistical models combined with network analyses were utilized to assess relationships between metabolites and the outcome. Finally, prioritized metabolites were validated using data from an ancillary study of the Childhood Asthma Management (CAMP) cohort with similar characteristics to PASS. RESULTS: Ninety metabolites were significantly associated with adrenal suppression, of which 57 also could discriminate adrenal status. While 26 metabolites (primarily steroids) were present at lower levels in the adrenal insufficient patients, 14 were significantly elevated in this group; the top metabolite, mannitol/sorbitol, was previously associated with asthma exacerbations. Network analyses identified unique clusters of metabolites related to steroids, fatty acid oxidation, and nucleoside metabolism, respectively. Four metabolites including urocanic acid, acetylcarnitine, uracil, and sorbitol were validated in CAMP cohort for adrenal suppression. CONCLUSIONS: Urinary metabolites differ among asthma patients on ICS, by adrenal status. While steroid metabolites were reduced in patients with poor adrenal function, our findings also implicate previously unreported metabolites involved in amino acid, lipid, and nucleoside metabolism.
Subject(s)
Adrenal Cortex Hormones , Asthma , Metabolomics , Humans , Asthma/drug therapy , Asthma/urine , Asthma/blood , Asthma/diagnosis , Child , Male , Female , Administration, Inhalation , Metabolomics/methods , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Biomarkers/urine , Biomarkers/blood , Adolescent , Metabolome/drug effects , Adrenal Insufficiency/diagnosis , Adrenal Insufficiency/blood , Adrenal Insufficiency/urine , Adrenal Insufficiency/etiology , Adrenal Insufficiency/drug therapy , Child, Preschool , Hydrocortisone/blood , Hydrocortisone/urine , Adrenal Glands/metabolism , Adrenal Glands/drug effects , Cohort StudiesABSTRACT
PURPOSE: Primary adrenal insufficiency (PAI) is a rare and life-threatening disease. A recent Endocrine Society guideline argued against hormonal monitoring of glucocorticoid replacement. However, about 50% of adolescents and young adults (AYAs) with chronic diseases are non-adherent to their treatment regimens. Therefore, suitable hormonal monitoring of glucocorticoid replacement would be highly desirable in AYAs with PAI. We investigated whether quantitative targeted gas chromatography-mass spectrometry urinary steroid metabolome analysis would be suitable for monitoring glucocorticoid replacement in AYAs with autoimmune PAI. METHOD: Retrospective analysis of 21 urinary steroid profiles of four AYAs aged 15.6⯱â¯2.0â¯years with autoimmune PAI on hydrocortisone and fludrocortisone treatment. 24-hr cortisol metabolite excretion rates (CMERs) were calculated using the sum of major seven urinary cortisol metabolites. CMERs were transformed into z-scores according to reference values of healthy age- and sex matched subjects. RESULTS: Three patients showed good treatment adherence (17 of 21 samples). Mean CMER of these samples was 7.4⯱â¯1.8â¯mg/m2/d, corresponding to a z-score of 1.8⯱â¯1.1. CMER reflected 59.7⯱â¯14.5% of prescribed hydrocortisone dosages. A forth patient displayed clinical symptoms of PAI during treatment. CMER was only 0.3â¯mg/m2 (-3.4â¯z), reflecting only 3.1% of prescribed hydrocortisone dosage, compatible with lack of treatment adherence. Thereafter, the parents supervised the intake of tablets and treatment adherence improved. CONCLUSION: Quantitative targeted GCMS steroid metabolome analysis could support monitoring of glucocorticoid replacement treatment in patients with PAI.
Subject(s)
Adrenal Insufficiency/urine , Autoantibodies/urine , Steroids/urine , Administration, Oral , Adolescent , Adrenal Insufficiency/drug therapy , Adrenal Insufficiency/metabolism , Adult , Autoantibodies/metabolism , Female , Gas Chromatography-Mass Spectrometry , Humans , Hydrocortisone/administration & dosage , Hydrocortisone/therapeutic use , Male , Retrospective Studies , Steroids/chemistry , Steroids/metabolism , Young AdultABSTRACT
OBJECTIVES: To determine if a urine sodium concentration could be used to rule out hypoadrenocorticism in hyponatraemic dogs. MATERIALS AND METHODS: Medical records were reviewed for hyponatraemic dogs (serum sodium<135 mmol/L) that had recorded urine sodium concentrations. Twenty hyponatraemic dogs were included: 11 diagnosed with classical hypoadrenocorticism and nine with non-adrenal causes of hyponatraemia. A Wilcoxon rank-sum test was used to compare results between groups. RESULTS: No dog with hypoadrenocorticism had a urine sodium concentration less than 30 mmol/L. Urine sodium concentration in dogs with hypoadrenocorticism was significantly higher (median 103 mmol/L, range: 41 to 225) than in dogs with non-adrenal illness (median 10 mmol/L, range: 2 to 86) (P<0·0005). Serum sodium concentrations were not significantly different between dogs with hypoadrenocorticism and dogs with non-adrenal illness. CLINICAL SIGNIFICANCE: These results suggest that urine sodium concentrations can be used to prioritise a differential diagnosis of hypoadrenocorticism in hyponatraemic dogs. A urine sodium concentration less than 30 mmol/L in a hyponatraemic dog makes classical hypoadrenocorticism an unlikely cause of the hyponatraemia. Nevertheless, because of the small sample size our results should be interpreted with caution and a larger follow-up study would be valuable.
Subject(s)
Adrenal Insufficiency/veterinary , Dog Diseases/urine , Hyponatremia/veterinary , Sodium/urine , Adrenal Insufficiency/complications , Adrenal Insufficiency/diagnosis , Adrenal Insufficiency/urine , Animals , Diagnosis, Differential , Dog Diseases/diagnosis , Dogs , Hyponatremia/etiology , Hyponatremia/urine , Pilot Projects , Predictive Value of Tests , Retrospective StudiesABSTRACT
In order to determine whether or not antidiuretic hormone (ADH) is essential to the inhibition of an acute water diuresis in adrenal insufficiency, the response to oral water loads was tested in rats with hereditary hypothalamic diabetes insipidus (DI) which lack ADH. It was found that 60 min after water loads of 3 or 5% of body weight urine flow was significantly lower and urine osmolality significantly higher in adrenalectomized DI rats than in the same DI rats before removal of their adrenal glands. The efficacy of gluco- and mineralocorticoids in reversing the inhibition was then determined in the same adrenalectomized DI rats. Prednisolone alone, administered either acutely or chronically, restored the response in urine flow to that seen in the same rats before adrenalectomy, but failed to correct the defect in urinary dilution. Aldosterone when given alone tended to correct the diluting ability but not the response in urine flow. When these two adrenal cortical hormones were given simultaneously, both the urine flow and urine osmolality were nearly identical to what they had been in the same DI rats before adrenalectomy. These studies strongly suggest (a) that ADH is not essential to the inhibition of an acute water diuresis in adrenal insufficiency, although it may abet the inhibition in individuals without diabetes insipidus, which can elaborate ADH; and (b) that both gluco- and mineralocorticoids are required in adrenal insufficiency in order to fully restore the water diuresis as judged by the dual criteria of urine flow and urine osmolality.
Subject(s)
Adrenal Insufficiency/urine , Aldosterone/pharmacology , Diuresis , Prednisolone/pharmacology , Vasopressins/pharmacology , Water-Electrolyte Balance , Adrenal Glands/physiology , Adrenal Insufficiency/drug therapy , Adrenalectomy , Animals , Diabetes Insipidus/physiopathology , Diabetes Insipidus/urine , Female , Glomerular Filtration Rate , Kidney/physiopathology , Male , Osmolar Concentration , Rats , Sodium/metabolism , Vasopressins/blood , Vasopressins/metabolism , Vasopressins/urineABSTRACT
BACKGROUND: A number of previous studies have suggested that adrenal suppression occurs in asthmatic children treated with high-doses of inhaled glucocorticoids (IGC). This study was designed to determine the frequency of adrenal suppression in children with severe asthma treated with recommended doses of IGC: namely 500-1,000 microg/day of fluticasone propionate or the equivalent of budesonide (1,000-2,000 microg/day) for a period of at least 12 months. METHODS: Early morning cortisol (F) and ACTH serum levels were measured in 27 severe asthmatics aged 6-16 years old. The children underwent a low dose ACTH test (1 microg/1.73 m2) with a parallel glucose measurement. Twenty-four hour urine collection was performed before examination for free F (UfF) and creatinine levels. There were no clinical manifestations of adrenal hypofunction in the analyzed children. RESULTS: Of the 27 patients, 22 had normal basal and post-stimulatory levels of F and normal UfF, and the other five (18.5%) had basal serum F levels of <400 nmol/l. Four of the five also had normal post-stimulatory levels of F and normal UfF. One child had a subnormal peak F value of 484 nmol/l during the ACTH test. None of the patients had a suppressed serum ACTH level, but an elevated ACTH level was found in four children. This study provided biochemical evidence of suboptimal adrenal function in one child in the examined group (3.7%) and a good response to stimulation in all the others, even in those with slightly reduced basal cortisol levels. CONCLUSION: This study showed that the use of fluticasone in doses of up to 1,000 microg/day (or the equivalent of budesonide) as long-term treatment of children with severe asthma did not substantially affect their adrenal function.
Subject(s)
Adrenal Insufficiency/chemically induced , Androstadienes/adverse effects , Anti-Asthmatic Agents/adverse effects , Asthma/drug therapy , Asthma/physiopathology , Budesonide/adverse effects , Adolescent , Adrenal Cortex Function Tests , Adrenal Insufficiency/blood , Adrenal Insufficiency/urine , Adrenocorticotropic Hormone/blood , Androstadienes/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/blood , Asthma/urine , Blood Glucose/metabolism , Budesonide/therapeutic use , Child , Female , Fluticasone , Humans , Hydrocortisone/blood , Hydrocortisone/urine , MaleABSTRACT
The impact of the synthetic glucocorticoid prednisone on adrenal steroid hormone production was examined using 24-hour urinary steroid hormone profiling. Five women, who were chronically taking low-dose prednisone, were tested, and the relevant literature was reviewed. As expected, adrenal glucocorticoid production, measured by urinary terminal cortisol and cortisone metabolites, was markedly suppressed compared to reference range values (p=0.03). Urinary cortisol and cortisone, reflecting circulating glucocorticoids, were decreased to a lesser extent than their terminal metabolites. Urinary dehydroepiandrosterone (DHEA) excretion was dramatically suppressed (p=0.03), while the downstream androgen metabolites androsterone and etiocholanolone were suppressed to a lesser extent. Aldosterone and tetrahydrocorticosterone production demonstrated modest suppression after prednisone administration, but allo-tetrahydrocorticosterone, which is highly sensitive to adrenocorticotropic hormone (ACTH) secretion, was suppressed to a greater extent. Prednisone administration results in a decrease in ACTH secretion by the anterior pituitary, suppressing synthesis of glucocorticoids, DHEA, and DHEA metabolites. Decreased glucocorticoid synthesis is adaptive, because prednisone is active at the glucocorticoid receptor, but suppression of DHEA synthesis is not mitigated by prednisone. DHEA is an important sex hormone precursor, neurosteroid, and endocrine and immune modulator; therefore, DHEA depletion may have significant adverse consequences in terms of sex hormone production, bone health, endocrine and immune system function, and neuropsychiatric status. Studies of DHEA replacement in patients taking prednisone for lupus demonstrate amelioration of some of these adverse effects.
Subject(s)
Adrenal Glands/drug effects , Adrenal Insufficiency/chemically induced , Anti-Inflammatory Agents/adverse effects , Prednisone/adverse effects , Adrenal Glands/metabolism , Adrenal Insufficiency/urine , Adult , Aldosterone/urine , Androsterone/urine , Anti-Inflammatory Agents/administration & dosage , Cortisone/urine , Dehydroepiandrosterone/urine , Etiocholanolone/urine , Female , Humans , Hydrocortisone/urine , Middle Aged , Prednisone/administration & dosageABSTRACT
Congenital adrenal hypoplasia is reported in two siblings. The first died at 16 months of purulent bronchopneumonia after a history of adrenal insufficiency. No gross adrenal tissue was found at autopsy and urinary steroids were not excreted in detectable amounts before death. In a subsequent uncomplicated pregnancy, extremely low estrogens were recorded in the last trimester. Analysis of steroids in the urine of the neontate by gas chromatography revealed virtual absence of 3 beta-hydroxy-5-ene steroids. These suggest hypoplasia of the fetal adrenal cortex. Metabolites of cortisol were excreted in normal amounts and responded adequately to ACTH stimulation. Neonatal hyponatremia was associated with subnormal excretion of corticosterone and aldosterone metabolites. It is proposed that in the perinatal period, the fetal zone is required for mineralocorticoid synthesis, possibly by providing essential precursor steroids, e.g. 21-hydroxypregnenolone.
Subject(s)
Adrenal Insufficiency/congenital , Dehydroepiandrosterone/urine , Adrenal Insufficiency/drug therapy , Adrenal Insufficiency/urine , Chromatography, Gas , Dehydroepiandrosterone/analogs & derivatives , Dexamethasone/therapeutic use , Fludrocortisone/therapeutic use , Humans , Infant , Infant, Newborn , MaleABSTRACT
Although free and conjugated dopamine (DA) constitute most of the plasma and urine catecholamine pool, the diagnostic significance of DA estimation for the evaluation of illness is not clear. We evaluated the clinical utility of DA estimation by measuring free and conjugated DA in patients with various illness. Patients with adrenal insufficiency did not show decreases in DA concentrations but did demonstrate reductions in free and conjugated plasma adrenaline (Ad). Patients with established stage of essential hypertension exhibited decreased plasma concentrations of free and conjugated DA, although they were hyperadrenergic. In patients with chronic renal insufficiency and failure, the free DA concentration in the urine decreased depending on the severity of renal impairment. Conversely, plasma concentrations of conjugated DA are higher in patients with chronic renal failure than in normal subjects. The high plasma concentrations of conjugated DA decreased dramatically following hemodialysis and renal transplantation. Urinary free DA excretion increased markedly following renal transplantation. In conclusion, the estimation of the free and conjugated DA in plasma and urine is clinically useful for the diagnosis of adrenal insufficiency, essential hypertension, and renal insufficiency and failure. It also can be used to monitor the effectiveness of hemodialysis and renal transplantation.
Subject(s)
Adrenal Insufficiency/diagnosis , Dopamine/analysis , Hypertension/physiopathology , Kidney Diseases/diagnosis , Kidney Transplantation/physiology , Adrenal Insufficiency/blood , Adrenal Insufficiency/urine , Animals , Dopamine/blood , Dopamine/urine , Humans , Kidney Diseases/blood , Kidney Diseases/urineABSTRACT
We investigated the renal transport of purine bases (uric acid, hypoxanthine and xanthine) after rapid and continuous ACTH loading tests in a patient with isolated ACTH deficiency, a rare cause of secondary adrenocortical insufficiency. Plasma uric acid concentration and the urinary ratio of uric acid/creatinine did not change in the rapid ACTH test, which did not increase plasma cortisol concentration. In the continuous ACTH loading test, the plasma concentration of uric acid and oxypurines (hypoxanthine and xanthine) decreased, and the urinary excretion and fractional clearance of them increased as well as the plasma concentrations and urinary excretion of cortisol. These findings suggest that glucocorticoid directly affects the common renal transport pathway for uric acid, hypoxanthine, and xanthine.
Subject(s)
Adrenal Cortex , Adrenal Insufficiency/physiopathology , Adrenocorticotropic Hormone/deficiency , Cosyntropin , Hypoxanthine/urine , Uric Acid/urine , Xanthine/urine , Adrenal Insufficiency/etiology , Adrenal Insufficiency/urine , Aldosterone/blood , Cosyntropin/administration & dosage , Gonadotropins, Pituitary/blood , Humans , Hypoxanthine/blood , Infusions, Intravenous , Kidney/physiopathology , Male , Middle Aged , Pituitary Hormone-Releasing Hormones/blood , Renin/blood , Uric Acid/blood , Xanthine/bloodABSTRACT
We investigated the influence of dose distribution in hydrocortisone replacement therapy on urine free cortisol excretion. To this end, we measured 24-hour urine free cortisol (24-h UFC) in 13 patients with hypocortisolism. The patients took 25 mg hydrocortisone/day according to the following schedules: either a single 25 mg hydrocortisone dose at 8:00 a.m., or 15 mg hydrocortisone at 8:00 a.m. and 10 mg hydrocortisone at 2:00 p.m., or 5 mg hydrocortisone at 8:00 a.m., 10:00 a.m., 2:00 p.m., 6:00 p.m. and 10:00 p.m. 24-h UFC decreased significantly with increasing division of the daily 25 mg hydrocortisone dose. When taking 25 mg hydrocortisone in a single morning dose, the mean 24-h UFC was 649 +/- 52 nmol/day (mean +/- SEM). When the daily dose was divided into doses of 15 mg and 10 mg hydrocortisone, 24-h UFC was reduced by 28 % to 466 +/- 39 nmol/day (p < 0.002). After division into five doses of 5 mg, 24-h UFC was reduced by 42.8 % to 371 +/- 36 nmol/day (p < 0.001) compared to the single 25 mg dose. These data demonstrate that consideration of the dose distribution in hydrocortisone replacement therapy when analysing 24-h UFC is of clinical importance.
Subject(s)
Adrenal Insufficiency/drug therapy , Adrenal Insufficiency/urine , Hydrocortisone/administration & dosage , Hydrocortisone/urine , Administration, Oral , Adult , Aged , Creatinine/urine , Drug Administration Schedule , Female , Hormone Replacement Therapy/methods , Humans , Male , Middle Aged , Urine/chemistryABSTRACT
The application of 2 special methods to the pathogenetic elucidation of idiopathic Addison's disease is discussed in the light of a clinical case. In accordance with the literature, this patient with idiopathic Addison's disease showed a normal adrenomedullary response (as gauged by the catecholamine excretion and the increase in plasma renin activity) to 2-deoxy-D-glucose administration. Moreover, IgG antibodies were demonstrable in the patient's serum with respect to adrenocortical antigens of the cytoplasmic components of the endocrine cells of the zona glomerulosa and zona fisciculata.
Subject(s)
Adrenal Insufficiency/immunology , Adrenal Glands/drug effects , Adrenal Insufficiency/blood , Adrenal Insufficiency/urine , Antibody Formation , Catecholamines/urine , Deoxyglucose/pharmacology , Female , Fluorescent Antibody Technique , Humans , Immunoglobulin G/analysis , Middle Aged , Renin/blood , Stimulation, ChemicalABSTRACT
The cortisol secretion rate was determined in 18 children according to a modified and simplified method. In 7 cases the determination was repeated after stimulation with synthetic ACTH. 12 of these children suffered from diseases which may affect glucocorticoidsteroid production and the remaining 6 children served as normal controls. In some cases the plasma 11-hydrocorticoid level and urinary excretion of 17-ketogenic steroids were additionally determined. Differences in adrenal function were noted in 2 patients with congenital adrenal hyperplasia (one of the salt-losing type, the other nonsalt-losing type) and 5 patients with adrenal insufficiency. A normal cortisol secretion rate was found in 3 children with diverse disturbances of carbohydrate metabolism, as well as in a child with subtotal adrenalectomy. The clinical value of the determination of the cortisol secretion rate is discussed and was found to be a more reliable indicator of glucocorticoid activity than other parameters.
Subject(s)
Hydrocortisone/metabolism , Secretory Rate , 11-Hydroxycorticosteroids/blood , 17-Ketosteroids/urine , Adolescent , Adrenal Cortex/drug effects , Adrenal Cortex Function Tests , Adrenal Insufficiency/blood , Adrenal Insufficiency/urine , Adrenalectomy , Adult , Child , Cosyntropin/pharmacology , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/urine , Female , Humans , Stimulation, ChemicalABSTRACT
CONTEXT: P450 oxidoreductase deficiency (PORD) is a unique congenital adrenal hyperplasia variant that manifests with glucocorticoid deficiency, disordered sex development (DSD), and skeletal malformations. No comprehensive data on genotype-phenotype correlations in Caucasian patients are available. OBJECTIVE: The objective of the study was to establish genotype-phenotype correlations in a large PORD cohort. DESIGN: The design of the study was the clinical, biochemical, and genetic assessment including multiplex ligation-dependent probe amplification (MLPA) in 30 PORD patients from 11 countries. RESULTS: We identified 23 P450 oxidoreductase (POR) mutations (14 novel) including an exonic deletion and a partial duplication detected by MLPA. Only 22% of unrelated patients carried homozygous POR mutations. p.A287P was the most common mutation (43% of unrelated alleles); no other hot spot was identified. Urinary steroid profiling showed characteristic PORD metabolomes with variable impairment of 17α-hydroxylase and 21-hydroxylase. Short cosyntropin testing revealed adrenal insufficiency in 89%. DSD was present in 15 of 18 46,XX and seven of 12 46,XY individuals. Homozygosity for p.A287P was invariably associated with 46,XX DSD but normal genitalia in 46,XY individuals. The majority of patients with mild to moderate skeletal malformations, assessed by a novel scoring system, were compound heterozygous for missense mutations, whereas nearly all patients with severe malformations carried a major loss-of-function defect on one of the affected alleles. CONCLUSIONS: We report clinical, biochemical, and genetic findings in a large PORD cohort and show that MLPA is a useful addition to POR mutation analysis. Homozygosity for the most frequent mutation in Caucasians, p.A287P, allows for prediction of genital phenotype and moderate malformations. Adrenal insufficiency is frequent, easily overlooked, but readily detected by cosyntropin testing.